EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment

Laize Sílvia Dos Anjos Botas Beca, Vivian Mumbiro, Mutsa Bwakura, Hilda A Mujuru iD, Shepherd Mudzingwa, Alfredo Tagarro iD, Sara Domínguez-Rodríguez iD, Victor Musiime iD, Damalie Nalwanga iD, W Chris Buck iD, Jahit Sacarlal, Chishala Chabala und 6 weitere

Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)

DOI: 10.1093/jac/dkag281 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 20.08.2026. Verfasst von Laize Sílvia Dos Anjos Botas Beca und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Lúrio University, Nampula, Mozambique. Hauptthemen laut MEDLINE: Anti-HIV Agents, Dideoxynucleosides, HIV Infections, Lamivudine. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership (EDCTP2) program, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lamivudine and abacavir are key components of first-line paediatric antiretroviral therapy (ART). Rifampicin is part of drug-sensitive TB treatment in children. Rifampicin induces UDP-glucuronosyltransferases and renal transporters and inhibits gastrointestinal transporters involved in the pharmacokinetics of abacavir and lamivudine, but pharmacokinetic data on this potential interaction in infants are scarce.

Objective

To evaluate the effect of rifampicin on the pharmacokinetics of abacavir and lamivudine in infants aged 28–365 days and weighing >3 kg.

Methods

This pharmacokinetic sub-study was nested within the EMPIRICAL trial (NCT03915366). Eighteen infants from Mozambique, Uganda, Zambia and Zimbabwe received once-daily fixed-dose abacavir/lamivudine with dolutegravir according to WHO guidelines. Five infants received ART alone and 13 received ART plus rifampicin-based tuberculosis treatment. Abacavir/lamivudine dosing was unchanged during rifampicin co-treatment. Six plasma concentrations were measured over 24 h and analysed using non-compartmental pharmacokinetic analysis.

Results

Median (IQR) age and weight were 6.8 (5.2–10.2) months and 6.0 (5.3–6.8) kg, respectively, and were comparable between groups. Abacavir exposure was comparable with and without rifampicin (AUC0–24h: 21.9 versus 21.0 h mg/L; Cmax: 6.2 versus 6.3 mg/L, respectively). Lamivudine exposure was also comparable (AUC0–24h: 12.6 versus 12.4 h mg/LL, respectively). The slightly higher Cmax (2.4 versus 1.9 mg/L) in the rifampicin group is probably due to interindividual variability or increased absorption from rifampicin's inhibition of gastrointestinal drug transporters, and considered not clinically relevant.

Conclusions

Rifampicin co-treatment had minimal impact on abacavir and lamivudine pharmacokinetics in infants. Dose adjustment of abacavir/lamivudine is not required during rifampicin-containing tuberculosis treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsDideoxynucleosidesHIV InfectionsLamivudineRifampinFemaleHumansInfantMaleAbacavirAntibiotics, AntitubercularDolutegravirDrug InteractionsHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesUgandaDrug Combinations

Substanzen

Abacavirabacavir, lamivudine drug combinationAnti-HIV AgentsAntibiotics, AntitubercularDideoxynucleosidesDolutegravirHeterocyclic Compounds, 3-RingLamivudineOxazinesPiperazines

Autor:innen und Institutionen

  • Department of Pharmacy, Lúrio University, Nampula, Mozambique.
  • College of Health Sciences, Clinical Research Centre, University of Zimbabwe, Harare, Zimbabwe.
  • Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12)-Fundación Biomédica del Hospital Universitario 12 de Octubre (FIB-H12O) Madrid, Spain.
  • Department of Pediatrics, Hospital Universitario Infanta Sofia, SERMAS, Madrid, Spain.
  • Faculty of Medicine and Health Sciences, Makerere University, Kampala, Uganda.
  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.

ORCID-Profile: Hilda A Mujuru, Alfredo Tagarro, Sara Domínguez-Rodríguez, Victor Musiime, Damalie Nalwanga, W Chris Buck, David M Burger, Tom G Jacobs

Förderung

  • European and Developing Countries Clinical Trials Partnership (EDCTP2) program
  • European Union

Zitieren

APA

Beca, L. S. D. A. B., Mumbiro, V., Bwakura, M., Mujuru, H. A., Mudzingwa, S., Tagarro, A., Domínguez-Rodríguez, S., Musiime, V., Nalwanga, D., Buck, W. C., Sacarlal, J., Chabala, C., Chansa, B. N., Rojo, P., Burger, D. M., Moraleda, C., Jacobs, T. G., & EMPIRICAL Clinical Trial Group (2026). Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment. Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag281

Vancouver

Beca LSDAB, Mumbiro V, Bwakura M, Mujuru HA, Mudzingwa S, Tagarro A, et al. Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment. Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag281

BibTeX
@article{Beca2026,
  author = {Beca, Laize Sílvia Dos Anjos Botas and Mumbiro, Vivian and Bwakura, Mutsa and Mujuru, Hilda A and Mudzingwa, Shepherd and Tagarro, Alfredo and Domínguez-Rodríguez, Sara and Musiime, Victor and Nalwanga, Damalie and Buck, W Chris and Sacarlal, Jahit and Chabala, Chishala and Chansa, Bwendo Nduna and Rojo, Pablo and Burger, David M and Moraleda, Cinta and Jacobs, Tom G and EMPIRICAL Clinical Trial Group, EMPIRICAL Clinical Trial Group},
  title = {Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {9},
  doi = {10.1093/jac/dkag281}
}
Kostenlos starten →